Pharmacogenetics of Antidepressant-Induced Disinhibition
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Aged 6 - 24 years [+3]
Inability of parent/legal guardian to give informed consent [+3]